The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...

Evotec appears to have rebuffed Halozyme’s $2.1 billion acquisition attempt. Elsewhere, Argenx has another blockbuster target ...

In buying Westlake-backed Kate Therapeutics, Novartis gets a handful of preclinical gene therapies targeting diseases like ...

The startup, Pep2Tango, is combining four methods of accelerating weight loss into one medicine in the hopes of developing a ...

Howard Chang will take over as chief scientific officer and senior VP of research as the biotech searches for more ways to ...

President-elect Donald Trump on Friday named Johns Hopkins University surgeon Marty Makary to lead the Food and Drug ...

Venture capital firms incubate, grow and finance dozens of drug companies each year. Follow the money they channel into the ...

Despite plans to shutter 1,200 stores, the company’s chief clinical trials officer said the pharmacy giant remains committed ...

Built around research by Stanford scientist Carolyn Bertozzi and MIT researcher Jessica Stark, Valora Therapeutics is ...

The restructuring follows the company's receipt of a letter from the FDA citing "deficiencies" in its approval application for diabetes drug Zynquista.

Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...

The drug, called icotrokinra and developed together with Protagonist Therapeutics, is an oral peptide designed to tamp down ...